针对患有血液性恶性瘤的血造细胞移植后或CAR T细胞治疗后患者的疫苗计划建议和更新
Gemma Reynolds1,2,3, Victoria G Hall1,2, Benjamin W Teh1,2
1Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria, Australia.
输血细胞移植 (HCT) 和细胞疗法后的再接种疫苗对于预防感染至关重要. 本综述综合了关于疫苗疗效的指导方针和证据,重点关注较新的配方和最佳时机,以改善患者的治疗结果.
科学领域:
- 免疫学和血液学 免疫学和血液学
- 疫苗学 疫苗学 疫苗学
- 瘤科 支持性护理
背景情况:
- 再接种疫苗是血造细胞移植 (HCT) 和细胞疗法之后的必要措施,以预防疫苗可预防的感染.
- 现有的疫苗接种计划需要综合,在这个人群中新疫苗的证据需要评估.
- 细胞疗法的再接种方案比HCT的定义要少.
研究的目的:
- 根据HCT,审查和综合国家,国际和专家共识的疫苗接种计划.
- 提出关于新型疫苗配方 (肺炎球菌,杆菌,COVID-19) 在患有血液性恶性瘤的患者中有效性的证据.
- 突出重复接种疫苗后细胞疗法的关键考虑因素,包括疫苗反应和时间.
主要方法:
- 文献综述综合了特定疫苗的疫苗接种计划和证据.
- 对接受HCT和细胞治疗的患者的疫苗疗效数据的分析.
- 确定影响再接种成功的关键因素,如疫苗反应和血清流行率.
主要成果:
- 证据支持在HCT接受者中使用新型肺炎球菌,菌和COVID-19疫苗配方.
- 在HCT后的疫苗接种计划已经建立,但细胞治疗后的指导方针不那么明确.
- 疫苗反应不佳和血清流行率的保存是需要进一步调查的重大挑战.
结论:
- 优化HCT后的再接种策略和细胞疗法对于减少与感染相关的发病率和死亡率至关重要.
- 需要进一步的研究来评估新疫苗和计划的免疫性和现实世界的有效性.
- 未来的研究应该将疫苗反应与细胞治疗目标相关联,以完善个性化疫苗接种方法.
更多相关视频
09:34Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
Published on: February 17, 2022
06:08Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model
Published on: February 10, 2023
相关概念视频
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Bone Marrow Sampling and Transplants
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
Tumor Immunotherapy
Stem Cell Therapy for Tissue Regeneration
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
Regulation of Hematopoietic Stem Cells
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
